Nuvalent Files Q1 2025 10-Q, Details Drug Pipeline
Ticker: NUVL · Form: 10-Q · Filed: May 8, 2025 · CIK: 1861560
| Field | Detail |
|---|---|
| Company | Nuvalent, INC. (NUVL) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, drug-development, financials
TL;DR
Nuvalent's Q1 2025 10-Q is out, showing R&D spend and pipeline updates for drugs like Neladalkib.
AI Summary
Nuvalent, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations, including details on its discovery programs and specific drug candidates like Neladalkib. The filing also covers equity transactions and research and development expenses for the first quarter of 2025.
Why It Matters
This filing provides investors with an update on Nuvalent's financial health and progress in its drug development pipeline, particularly concerning its oncology programs.
Risk Assessment
Risk Level: medium — Biotech companies like Nuvalent face inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial and operational data)
- 2025-03-31 — As of Date (Date as of which financial information is reported)
- 2024-01-01 to 2024-03-31 — Prior Year Q1 (Comparative period for financial results)
Key Players & Entities
- Nuvalent, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- Neladalkib (drug_candidate) — Mentioned in relation to discovery programs
- One Broadway, 14th Floor, Cambridge, MA 02142 (address) — Company's business and mailing address
- 508-446-2272 (phone_number) — Company's business phone number
FAQ
What were Nuvalent's research and development expenses for the first quarter of 2025?
Research and development expenses for the period January 1, 2024, to March 31, 2024, are detailed in the filing, with the Q1 2025 figures also presented.
What is the status of Nuvalent's drug candidate Neladalkib as of March 31, 2025?
Neladalkib is mentioned as a drug candidate within Nuvalent's discovery programs, with data presented for the periods January 1, 2025, to March 31, 2025, and January 1, 2024, to March 31, 2024.
What is Nuvalent's fiscal year end?
Nuvalent's fiscal year ends on December 31.
What is the company's SIC code?
Nuvalent's Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
When was the TwoThousandTwentyOneStockOptionAndIncentivePlan established?
The TwoThousandTwentyOneStockOptionAndIncentivePlan was established between July 1, 2021, and July 31, 2021.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Nuvalent, Inc. (NUVL).